Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 19/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4784565 | 0.94 | P2RY12 (0.64) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4740695 | 0.94 | P2RY12 (0.64) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4737846 | 0.93 | P2RY12 (0.63) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4742900 | 0.93 | P2RY12 (0.56) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4740350 | 0.93 | P2RY12 (0.64) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4737154 | 0.93 | P2RY12 (0.62) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4892514 | 0.92 | P2RY12 (0.55) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4738017 | 0.92 | P2RY12 (0.53) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4739433 | 0.92 | P2RY12 (0.66) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4742024 | 0.91 | P2RY12 (0.57) | P2RY12CYP2C9CYP3A4CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | P2RY12, P2RY13, P2RY11 | P2RY12 1/4885CYP2C9 759/4885CYP3A4 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.